Saturday, August 31, 2013

Weekend Reading: 2013 September Hepatitis C Newsletters

 

 September Newsletters
 
Each month, a small group of people devoted to HCV advocacy, publish a newsletter offering support and information to people afflicted with the hepatitis C virus. Included this month are additional links to personal stories, research and news.



For Liver Health Information
Call 1-800-GO-LIVER
 
 September 2013 edition of the Liver Lowdown

From The American Liver Foundation

In This Issue

Alcohol and Drug Abuse Recovery Is Possible – With Determination, Assistance and Acknowledgement

HOW MUCH DO YOU KNOW ABOUT THE IMPORTANCE OF YOUR LIVER?

WELCOME TO OUR LATEST MICROSITE: A COMPREHENSIVE RESOURCE ABOUTHEPATIC ENCEPHALOPATHY (HE)

Learn more about what the liver is and what it does for your body
 
 
 
 
The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education
 
September Newsletter
 
In This Issue:
 
 
Personal Stories
Stories written by ordinary people sharing personal experiences living with hepatitis C.  
 
August 2013 - One Mans Story - Lemons to Lemonade
 
 Connect With HCV Advocate

Twitter Facebook




HepCBC Hepatitis C Education and Prevention Society

HepCBC’s MONTHLY NEWSLETTER

September Newsletter (PDF)  

The hepc.bull, has been “Canada’s hepatitis C journal” since the late 1990′s and has been published nonstop since 2001. The monthly newsletter contains the latest research results, government policy changes, activities and campaigns you can get involved in, articles by patients and caregivers, and a list of support groups plus other useful links.

ARTICLES IN THIS ISSUE include:

Liver Transplant Patients from Outside Vancouver

 URGENT Request for Patient Input on SIMEPREVIR by September 11th

 NEW Online HCV Support Community on "Health Unlocked" Portal

NEW CIHR HIV-HCV Coinfection Mgmt & Treatment Guidelines

World Hepatitis Day in BC, part II and WHD throughout Canada

 CATIE article on new HCV Drugs: "Easier to Take and More Cures"

 NAULI YOGA for Liver Massage

SVR Honour Roll - people who have been 100% cured

And More!

Stay Connected

Twitter Facebook


 
Hep C Connections

Our newsletter is sent out for free electronically on the 1st of every month. To subscribe, please send your email address to slh@hepc-connection.org.

August 2013  
Check Back For September Newsletter

 Facebook

 
 
GI & Hepatology News

 GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.

View Current Issue (VOL. 7 NO. 9 September 2013):
PDF | Interactive Version

In This Issue
Interferon-free regimen for HCV-1 Faldaprevir, deleobuvir, ribavirin combo proved effective in phase II clinical

Study characterizes HCV exacerbation course
.. acute exacerbation of chronic hepatitis is responsible for an unfavorable outcome in patients with chronic hepatitis. However, the majority of patients with acute exacerbation of chronic hepatitis C obtained an SVR, most probably because of the high frequency of HCV genotype 2 and IL-28-B CC genotypes in the case group, and possibly because the reactivation of a cell-mediated immune response may favor HCV clearance,” they said, adding that “ the more rapid progression to cirrhosis and the risk of hepatocellular carcinoma strongly warrant the early initiation of anti-HCV therapy for acute exacerbation of chronic hepatitis C patients.

Guide to help with patient questions about colonoscopy
The GI societies recommend colonoscopy for colorectal cancer screening beginning at age 50 for all average risk people.
 
Do I even need a colonoscopy?
Is there a cheaper test that would be just as good for colon cancer screening?

 Risk score IDs hep C patients likely to get HCC
A risk score derived from four simple test results readily obtained during routine care may help identify patients with chronic hepatitis C who are most at risk for developing hepatocellular carcinoma, according to results of a retrospective study. The score could enable physicians to target only the highest-risk patients for annual surveillance for malignant hepatic nodules, which is crucial because current screening methods are too invasive, too expensive, and too low-yield to be applied broadly across all risk groups.

High BMI appears to cause gallstones
A n elevated body mass index is not just associated with symptomatic gallstone disease, it ap- pears to cause the disease, according to a report published in Hepatology (doi:10.1002/hep.26563).
 
Liver Health Updates
Liver health and research articles available @ Hepatitis C Research and Liver Health
 
Interferon-Sparing Therapies - 2013 News and Clinical Research
 
Connect With AGA

Twitter  Facebook


 
  
CAP Hepatitis C Literature Review
Monthly Pubmed Review of the most relevant research on HCV

August Literature Review
Check back for September Review
 
Hepatitis C Choices
5th edition Free Online Book
 
Advocacy Map
Do you want to know who represents you and what we are up against? See our tool
"Hepatitis By The Numbers" Advocacy Map
 
 Hepatitis C Facts And Figures
Hepatitis C is the most common blood-borne chronic viral illness in the U.S.

At least 170 million people worldwide are infected with the hepatitis C virus.

An estimated 20,000 new cases of hepatitis C occur each year in the U.S. Approximately 75% of people exposed to the hepatitis C virus become chronically infected.

Most people with chronic hepatitis C are unaware that they are infected because HCV is often asymptomatic until advanced liver damage develops.

Hepatitis C is the leading cause of chronic liver disease in the U.S. HCV disproportionately affects medically underserved populations including the homeless, Native Americans, African-Americans, persons of Hispanic descent, and Asian/Pacific Islanders.

1 in 10 African-Americans between 40-60 are HCV positive. HCV seroprevalence rates of up 22% have been demonstrated among homeless persons.

The HCV seroprevalence rates among African-Americans (3.2%) and Mexican-Americans (2.1%) are significantly higher than in the general U.S. or Caucasian American populations.

Chronic liver disease/cirrhosis and viral hepatitis are more common causes of death in Native Americans, Asian/Pacific Islanders, and Hispanic Americans than among the general U.S. population.

Those with a low socioeconomic status and limited education are disproportionately affected by hepatitis C.

Approximately 25 to 30% of Americans with HIV/AIDS are coinfected with the hepatitis C virus.

HIV/HCV coinfected persons have twice the risk of cirrhosis and a six-fold increased risk of liver failure compared to people with HCV alone.

HCV-related end-stage liver disease is now a leading cause of death among HIV-positive persons.

 Approximately 20% to 30 % of people with chronic hepatitis C develop cirrhosis.

Each year, 1% to 4% of people with HCV-related cirrhosis develop liver cancer.

The incidence of liver cancer in the U.S. more than doubled between 1975 and 1998.

The number of new cases of liver cancer and the associated number of liver cancer deaths are expected to double again in the United States over the next 10 to 20 years.

Liver cancer is currently the most lethal and fastest growing cancer in the US.

The majority of the cases are caused by viral hepatitis.

Hepatitis C is the leading cause of adult liver transplantation in the U.S. Since 1990, the number of people with HCV w ho underwent liver transplantation increased over twelve- fold.

An estimated 15,000 people die each year in the U.S. of hepatitis C disease.

The death rate in Oregon has tripled since 1998.

The number of hepatitis C deaths each year in the U.S. is greater than the number of deaths caused by melanoma, cervical cancer, uterine cancer, thyroid cancer, or Hodgkin's lymphoma.

Without intervention, complications associated with HCV-related cirrhosis are projected to increase dramatically by 2020: liver failure by 106%, liver cancer by 81%, and liver-related deaths by 180%.

2013-Hepatitis C Full Text Articles available @ Hepatitis C Research and Liver Health

Stay Connected With CAP

Facebook
 
 
 
The Hepatitis C Trust is the national UK charity for hepatitis C. It was founded and is now led and run by people with personal experience of hepatitis C and almost all of our Board, staff and volunteers either have hepatitis C or have had it and cleared it after treatment.
 
All the latest news about hepatitis C
 
The updates from The Hepatitis C Trust aim to bring you regular information on the work we are doing each month. Check back for September update 
 
If you would like to receive our updates by email, let me know saskia.whitfield@hepctrust.org.uk
 
In The Media
Petra Wright is interviewed by Perth Internet TV at the 80s Rewind Festival from The Hepatitis C Trust Plus. The video also features a short film from The World Hepatitis Alliance.

Treatment Diaries
A series of "Treatment Diaries" written by people undergoing HCV therapy . Provided below is one woman's journey.
 
Gemma's Treatment Diary
Gemma is the Campaigns and Events Manager at The Hepatitis C Trust. She will be periodically sharing her treatment experience of the phase III AbbVie trial. It is important to remember that many patients have quite different experiences with treatment. The Hepatitis C Trust aims only to offer impartial information and does not necessarily endorse the opinions held by one patient. However, we wish Gemma all the best on her journey and feel that the diary may be helpful for others looking for an insight into the treatment journey.
 
Chronic hepatitis C: Treat or wait?
A collection of news articles and research weighing the risks and benefits of treating HCV now versus waiting for future therapies  available @ Hepatitis C Research and Liver Health
 
Connect With Hepatitis C Trust
 
Twitter  Facebook
 
 
Hep Chat e-newsletter

Hep Chat is Hepatitis Victoria's electronic newsletter that is published 8 times a year

To subscribe to HepChat click here.
 
Suggestions for relieving some of the more common symptoms experienced by people
with hepatitis C
 
Cognitive ability refers to a person’s ability to think clearly and to concentrate. Some people with hepatitis C notice a change in their cognitive ability. A person may find they cannot concentrate for long periods of time or that their thought processes seem slower than usual. Some people may have difficulty coming up with words they want to say, or just feel mentally tired. These cognitive changes are sometimes called ‘brain fog’. Like other symptoms of hepatitis C, cognitive changes can come and go. These symptoms can be caused by other things unrelated to hepatitis C, including depression and anxiety.
 
It is a good idea to discuss these symptoms and how to manage them with a health professional such as a counselor or doctor. There are things you can do to lessen the impact of ‘brain fog’ on your life:
 
Make lists and work through them.
Give yourself more time to complete tasks.
Discuss important decisions with someone you trust.

  Continue reading @ Hepatitis Australia
 
Updates
Hepatitis C Research and Liver Health
Hepatitis C Neuropsychiatric symptoms-“brain fog” 

 Connect With Hepatitis Victoria

    Twitter    Facebook
 
 
 
 
Supporting people in Scotland living with HIV or Hepatitis C

Waverley Care is Scotland’s leading charity providing care and support to people living with HIV or Hepatitis C. As part of our work we also strive to raise awareness of these conditions and their prevention.

Here on our website you will find news and information about Waverley Care, HIV and Hepatitis C, Our Services and how you can Support our Work.
 

Social Support
 
Twitter  Facebook
 

Healthy You


 
 
Get and stay healthy with this trusted monthly newsletter from NIH.
 
Download a PDF version of NIH News in Health or click here to read this months health news.

Connect with NIH on Twitter and Facebook
 
Twitter   Facebook
 
 
Hot Topics For The Month Of August
 Results of the Phase II trial, sponsored and led by the National Institutes of Health, suggest that a regimen of sofosbuvir and ribavirin was highly effective in clearing the virus and well tolerated in two difficult-to-treat groups—patients with severe liver damage and African Americans. Both groups were comprised of those with genotype-1 HCV, which accounts for 70% of all HCV infections.
Read more here....

Viral Levels Reduced in Patients with Chronic Hep C Infections Treated with Interferon-Free Regimen

The JAMA Report


Video Source

Strong association of type 2 diabetes mellitus with HCV infection
 Advancing age, increased weight, and HCV genotype 3 are independent predictors of type 2 diabetes in HCV seropositive patients, and there is a statistically significant association of cirrhosis observed with type 2 diabetes mellitus.

Healthy You

Eating apples, grapes and blueberries may lower risk of type 2 diabetes


Video Source
 
A research consortium known as the Hepatitis C Therapeutic Registry and Research Network, or HCV-TARGET, has joined forces with the FDA to share national data on how newly approved therapies for hepatitis C are used and managed in routine practice
 
In Hepatitis C patients with advanced liver fibrosis or cirrhosis (METAVIR F3 or F4) 12 weeks all oral treatment with simeprevir and sofosbuvir with or without ribavirin led to SVR4 rates of 96% and 100%, respectively

 Once-daily simeprevir and sofosbuvir with or without ribavirin was generally safe and well tolerated  
 
 Santaris Pharma A/S Completes Enrollment in Phase 2 Clinical Trial of Miravirsen In Null Responders to Pegylated Interferon and Ribavirin for the Treatment of the Hepatitis C Virus

-- Enrollment also begins in study investigating miravirsen in combination with telaprevir and ribavirin in null responders to pegylated interferon and ribavirin --
 
Vertex’s VX-135 partial hold signals heightened FDA scrutiny toward HCV drugs
Vertex Pharmaceuticals’ (NASDAQ:VRTX) hepatitis C virus (HCV) drug VX-135 and the recent partial clinical hold placed on it signal heightened FDA scrutiny toward HCV drugs, experts said.
Still, most experts expressed optimism the partial hold will be removed and that the 200mg dose will advance.

Other therapies developed to treat HCV that are similar to VX-135, a direct-acting antiviral (DAA) have been shown to trigger only transient elevations in liver enzymes, which are less of a concern....

Mild ALT increases seem to be quite common with many DAAs, a second European expert added. Either the elevation associated with VX-135 must be higher or the frequency greater than what has been observed with other DAAs to merit the partial clinical hold, he speculated....
 
This issue is guest edited by Dr. Norah Terrault, explores the current topics and controversies in the field of liver transplantion, from refining the criteria used for selection, to managing infection before and after the operation.
 
Five major pharmaceutical companies are developing oral, interferon-free HCV treatment regimens based upon still-investigational direct-acting antiviral agents (DAAs) that target HCV proteins and their functions. The clinical trials experience to date indicates these DAA-based regimens have substantially higher cure rates, far better tolerability and safety, and a much lower pill burden
 
Could interferon-based therapies for chronic hepatitis C cause retinopathy?
To assess the incidence of retinopathy in patients with chronic hepatitis C being treated with interferon-based regimens and estimate the rate of resolution. A systematic literature search was performed to locate all relevant publications. Pooled incidence of retinopathy was calculated in patients treated with interferon or pegylated interferon. We also estimated the rate of discontinuation of treatment and resolution after the treatment was stopped
 
While patients with chronic hepatitis C virus (HCV) infection are treated in order to prevent liver-related morbidity and mortality, we rely on sustained virological response (SVR) as a virological biomarker to evaluate treatment efficacy in both clinical practice as well as in drug development.
However, conclusive evidence for the clinical benefit of antiviral therapy or validity of SVR as surrogate marker, as derived from trials randomizing patients to a treatment or control arm, is lacking.

In fact, the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) trial recently showed an increased mortality rate among interferon-treated patients compared to untreated controls. Consequently, the recommendation to treat patients with chronic HCV infection was challenged. 

Hey Grandma, Let's Get You Checked for Hep C
The prevalence of chronic hepatitis C virus (HCV) infection in the United States may have peaked over a decade ago, but there is convincing evidence that middle-aged and older adults born between 1945 and 1965 are at increased risk for infection. The most significant risk factor for chronic HCV infection is prior injection drug use, but the majority of adults with infection do not have this risk factor. Therefore, in additional to regular screening among high-risk groups, the US Preventive Services Task Force (USPTSF) now recommends 1-time screening for chronic HCV infection for adults born between 1945 and 1965.

While this recommendation may seem preposterous when thinking of your own Nana, do you really know what she was up to in 1968? There is good merit for the recommendation, which is discussed in this article.

Hepatitis C - A Look At Disease Progression 
 Researchers often reference a unique cohort of HCV patients when describing the natural history of hepatitis C. Never has there been a more perfect natural history study, in that - the known dates of infection were clear and precise. This for the most part is difficult to achieve since the time of acute HCV infection is often impossible to establish.

Of Interest

New Blog Explores ObamaCare in Bite-Size Portions
A Doc For Change

Aug 28, 2013

Ever wondered what you and your patients were really getting from the Patient Protection and Affordable Care Act? A new blog by NYC neurologist, Dr. Anthony Geraci, explores the 2,400 page document by breaking down the massive health care law section by section and writing about his experiences reading it – the good and the bad. The blog aims to inform and inspire those who want to educate themselves and improve the state of health care.

Source - The Doctors Channel

 
Posted by at No comments:
File Under , , ,

Merck demand triggers expanding patent war with Gilead over sofosbuvir


UPDATED: Merck demand triggers expanding patent war with Gilead over sofosbuvir

August 31, 2013 | By John Carroll

Gilead is rolling out its big legal guns to defend its control of the experimental hepatitis C drug sofosbuvir, one of the most valuable therapies in the industry's late-stage pipeline.

On Friday the company fired over Merck's bow, filing suit in the Northern District of California after Merck contacted the company a few weeks ago to stake a claim to 10% of the revenue generated by sofosbuvir. Merck ($MRK) wants Gilead ($GILD) to sublicense two of its hep C-related patents, according to the lawsuit. The pharma giant sells Victrelis (boceprevir), its recently approved hep C drug, which is likely to be swept away as sofosbuvir and companion therapies make it to the market, offering a treatment less likely to trigger side effects and quicker to quell the virus.

In a letter filed with the lawsuit, Merck's Pamela Demain, the executive director of corporate licensing, explained on Aug. 5 that Merck was seeking the 10% royalty based on the two patents: '499 and '712. And she set an August 31 deadline for a response, drawing a line in the legal sand.

Merck's terms: "Gilead shall pay Merck a 10% royalty on the Net Sales of Licensed Product … by Gilead, its distributors or sublicensees, including sales of Licensed Product that is co-packaged with one or more other pharmaceutical products, from the first sale of sofosbuvir until the expiration of the last to expire patent within the Licensed Patent Rights."

And that's just one of several legal fights brewing as an FDA marketing decision on sofosbuvir looms in early December.

In its first-half financial report, Gilead also notes that Roche is claiming control of sofosbuvir based on a 9-year-old, $168 million partnership it struck with Pharmasset, which Gilead bought for a whopping $11 billion in order to seize full ownership of sofosbuvir while it was still in midstage development. According to the SEC filing, Roche ($RHHBY) believes that its 2004 deal to develop a nucleoside polymerase treatment with Pharmasset gives it an exclusive license on sofosbuvir, which Roche claims is a "prodrug (or precursor) of PSI-6130."

Gilead says the arbitration demand filed by Roche is without merit, noting that the deal ended about two years after it began--long before it acquired the company.

The Roche move follows an effort by Idenix ($IDIX) in 2012 to establish that it was the first to invent sofosbuvir. "Our patent covers metabolites of sofosbuvir and RG7128. Idenix is attempting to claim a class of compounds, including these metabolites, in its pending patent application," notes Gilead.

The growing flank attack on the sofosbuvir patent highlights the increasingly complex relationships among pharma companies as they become more likely to partner with academics and biotechs to broaden their pipelines. Big Phase III programs often attract litigation, like Medivation's ($MDVN) claim on Aragon's cancer therapy, ARN-509, since acquired by J&J ($JNJ). And sometimes they win, as we saw when Onyx ($ONXX) successfully laid claim to a 20% royalty of Stivarga from Bayer after bristling over its similarities to their partnered drug Nexavar.

Gilead will spare no expense in this fight. Analysts believe that sofosbuvir is an almost certain blockbuster, with peak sales estimates hovering around $4 billion to $5 billion. It's the leader in a pack of programs which are in the process of rewriting the standard of care for hepatitis C as AbbVie ($ABBV), Bristol-Myers Squibb ($BMY), J&J and other rivals hustle to catch up. And the prospect of gaining even a slice of that action is worth a considerable sum in legal costs to any company that thinks it has an actionable claim.

A spokesperson for Merck told FierceBiotech Saturday that the company has "nothing to add at this time."

Related Articles:
Gilead's sofosbuvir cures some of the toughest hepatitis C cases
Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore
Gilead races to FDA after hep C blockbuster hopeful scores 4th win in PhIII

Read more: UPDATED: Merck demand triggers expanding patent war with Gilead over sofosbuvir - FierceBiotech http://www.fiercebiotech.com/story/merck-triggers-rapidly-expanding-patent-war-gilead-over-sofosbuvir-rights/2013-08-31#ixzz2davfY0DE
Subscribe at FierceBiotech 

Gilead Sues Merck Saying New Drug Won’t Infringe Patents

Gilead Sciences Inc. (GILD), the world’s largest maker of HIV medicines, sued Merck & Co. (MRK) seeking a court order that the experimental hepatitis C drug sofosbuvir won’t infringe patents.

Merck, which sold $502 million of its Victrelis hepatitis C drug last year, contacted Gilead this month requesting it license two patents Merck says are related to sofosbuvir, Gilead’s attorneys said a complaint filed today in federal court in San Francisco.

Merck, based in Whitehouse Station, New Jersey, asked Gilead to pay a 10 percent royalty on the net sales of the medicine until the patents expire, a request “meant to threaten Gilead” on the eve of U.S. regulatory approval of sofosbuvir, according to the complaint. Gilead seeks a judge’s declarations that the patents aren’t enforceable or infringed so it won’t have to license them to sell the medicine.

Gilead, based in Foster City California, said June 7 that sofosbuvir will receive a priority marketing review by U.S. regulators with a target review date of Dec. 8.

Hepatitis C attacks the liver and can lead to liver cancer. The virus affects about 150 million people worldwide and the market for new pills such as sofosbuvir is estimated at $20 billion.

Lainie Keller, a Merck spokeswoman, didn’t immediately respond to an e-mail after regular business hours seeking comment on the lawsuit.

The case is Gilead Sciences v. Merck, 13-04057, U.S. District Court, Northern District of California (San Francisco).

To contact the reporter on this story: Karen Gullo in San Francisco at kgullo@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

http://www.bloomberg.com/news/2013-08-31/gilead-sues-merck-saying-new-drug-won-t-infringe-patents.html
Posted by at No comments:
File Under , ,

Friday, August 30, 2013

Liver cancer due to chronic inflammation: tumour growth follows programmed cell death (apoptosis)

Liver cancer due to chronic inflammation: tumour growth follows programmed cell death (apoptosis)

Neuherberg, August 30, 2013.


Immunohistochemical stainings of Ki67 and pancytokeratin (Ki67 is stained brown, pancytokeratin is stained pink) indicate proliferation of hepatocytes (arrowheads) and biliary epithelial cells (arrows) in TAK1/RIP3-deficient mice. (Image: Helmholtz Zentrum München

The death of numerous liver cells in the context of chronic inflammation due to apoptosis, a form of programmed cell death, can promote the formation of tumour cells in the liver.

This insight significantly contributes to a better understanding of cellular processes in liver cancer development and thereby opens up new therapeutic approaches. A research team including scientists from the Helmholtz Zentrum München has reported this in the current issue of the scientific journal 'Cell Reports'.

Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death. The result is increased cell growth, also referred to as compensatory proliferation, which can lead to tumour development.

A distinction is made between the two most important forms of self-induced cell death, namely apoptosis (programmed cell death) and necroptosis (programmed necrosis), which are based on different cellular mechanisms. Until now, it was not clear which form of cell death is decisive for the development of malignant liver tumours. The team working with Professor Dr. Tom Luedde from the RWTH Aachen University Hospital and Professor Dr. Mathias Heikenwälder from the Institute of Virology at the Helmholtz Zentrum München (HMGU) has now been able to verify that apoptosis precedes the development of abnormal liver cells. The scientists, including Florian Reisinger from the Institute of Virology (HMGU) and Dr. Kristian Unger from the Research Unit Radiation Cytogenetics (HMGU) showed this using mouse models. Moreover they discovered that in contrast, necroptosis prevents uninhibited cell proliferation and consequently the development of liver cancer.

These findings could form the basis for new approaches to therapy for liver cancer, which until now has been a form of cancer that cannot be adequately treated and that kills 800,000 patients around the world each year. "We now know which cellular signalling pathways are involved in liver tumour development", explains Heikenwälder. "In a further step we want to develop new treatment options, for example, by attempting to pharmaceutically block the apoptosis itself or its signalling pathways. But any new therapy can also cause undesirable effects: In our experiments, we saw that blocking apoptosis under inflammatory conditions can result in bililary obstruction (cholestasis) in the context of liver inflammation."

In upcoming investigations, the scientists want to verify their findings on the development of liver cancer and search for active substances that inhibit apoptosis while simultaneously causing the mildest possible side effects. The objective is to further develop the acquired knowledge in the sense of translational research in order to provide concrete benefits for society.

Further information

Original publication:
Vucur, M. et al. (2013), RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling Caspase-8- and JNK-dependent compensatory cell proliferation. Cell Reports, doi: 10.1016/j.celrep.2013.07.035
Link to publication

http://www.helmholtz-muenchen.de/en/news/latest-news/press-releases-2013/press-release/article/22151/index.html
Posted by at No comments:
File Under ,

Hey Grandma, Let's Get You Checked for Hep C

Medscape Family Medicine > Best Evidence Review

Hey Grandma, Let's Get You Checked for Hep C
Charles P. Vega, MD
Aug 30, 2013

Best Evidence Review of the USPSTF Screening Recommendations for Hepatitis C

The Study
Moyer VA; US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Jun 25.
[Epub ahead of print]

Introduction
The prevalence of chronic hepatitis C virus (HCV) infection in the United States may have peaked over a decade ago, but there is convincing evidence that middle-aged and older adults born between 1945 and 1965 are at increased risk for infection. The most significant risk factor for chronic HCV infection is prior injection drug use, but the majority of adults with infection do not have this risk factor. Therefore, in additional to regular screening among high-risk groups, the US Preventive Services Task Force (USPTSF) now recommends 1-time screening for chronic HCV infection for adults born between 1945 and 1965.

While this recommendation may seem preposterous when thinking of your own Nana, do you really know what she was up to in 1968? There is good merit for the recommendation, which is discussed below.

Background to the Study
HCV infection is one of the most common chronic infections in the United States. Data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2002 indicated that the overall prevalence of HCV infection was 1.6% among adults aged 20-59 years.[1] This figure includes over 3 million adults with active infection, as defined by a positive HCV RNA test. Moreover, this testing probably underestimated the total prevalence of HCV infection because high-risk populations, including homeless and incarcerated adults, were not included in the research. In a study of over 400 homeless war veterans, the prevalence of HCV infection was 44.0%.[2]
Evidence of HCV infection is twice as common among women than men and among African Americans than white adults.[3] The most important risk factor for HCV infection is intravenous drug use. Nearly one half of the cohort that was positive for HCV infection in the NHANES study had this risk factor.[1] Other significant risk factors for HCV infection include receipt of blood transfusion before 1992, receipt of other blood products before 1987, and other drug use.[3] Sexual behavior is a less powerful risk factor HCV infection compared with HIV infection, but there is evidence that a history of multiple sexual partners is associated with a higher risk for HCV infection. Many individuals with HCV infection have overlapping risk factors for infection.

Why Screen All Baby Boomers?
Although the authors of the recommendations regarding screening for HCV infection note that the prevalence of HCV infection in the United States appeared to peak in 2001, there is another clear trend in the epidemiology of HCV infection that merits close attention. Persons born between 1945 and 1965 comprise approximately 27% of the total population of the United States, but they account for a disproportionate share of cases of HCV infection.[4] The prevalence of HCV infection in this age group is 3.25%, and approximately three quarters of active HCV infection cases are encountered among persons born between 1945 and 1965.

Moreover, and more important, persons who are currently in the fifth through seventh decades of life at this time are at the highest risk for complications from HCV infection. They account for 73% of mortality due to HCV infection, and this group is also at the highest risk for hepatocellular carcinoma and cirrhosis.[4] Therefore, the number of patients needed to treat with anti-HCV therapy in order to prevent additional cases of mortality is lower in this specific older cohort of adults compared with younger adults.

Therefore, it is not only the epidemiologic data that drive the new HCV screening recommendations from the USPSTF, but also an expectation that treatment of heretofore undiagnosed HCV infection can put a substantial dent in the broad clinical impact of HCV. The new recommendations call for 1-time screening for all adults born between 1945 and 1965 (B recommendation: high certainty that the net benefit is moderate, or moderate certainty that the net benefit is moderate to substantial). The anti-HCV antibody is test the best screening tool for these adults.

Limitations and Benefits of Age-Based Screening
Limitations
The authors identify the limitations of the new recommendations. Although age-based screening should identify more patients with HCV infection, they admit that this method may be less efficient than risk-based screening. The potential harms of screening include stigmatization, but also the more tangible and serious complications of the diagnostic work-up of liver disease.
The rate of major complications after percutaneous liver biopsy ranges between 0.09% and 2.3%, with a trend toward higher complication rates in older studies.[5] Use of ultrasonography to guide liver biopsy may reduce the risk for complications by 30%. However, the authors of the current review note that overall use of liver biopsy is declining with greater reliance on laboratory testing alone to guide treatment. This will reduce the potential harms of screening for HCV infection.
A more serious complication of a large screening campaign for HCV infection among older adults is overdiagnosis, meaning the discovery of infections which would have no impact on the course of the patient's life. Up to 25% of acute infections with HCV may be cleared and do not progress to chronic HCV infection.[6] Despite the high numbers of patients with chronic HCV infection, only 10%-15% develop cirrhosis. The mean interval from infection to cirrhosis is a matter of debate but is approximately 20 years, and patients without other cirrhosis risk factors, such as chronic alcohol misuse or hepatitis B infection, are less likely to develop cirrhosis.

Benefits of Screening
Nonetheless, acquiring HCV infection at an age older than 40 years is also associated with a higher risk for cirrhosis, making overdiagnosis less of an issue among older adults.[6] In addition, treatment of chronic HCV infection has resulted in significant improvements in morbidity and mortality outcomes.

In research from 5 large tertiary hospitals in which 530 patients were followed for over 8 years for mortality outcomes, patients with a sustained virologic response (SVR) experienced a 74% reduction in all-cause mortality and a 94% reduction in the risk for liver-related mortality or transplantation compared with patients who did not have an SVR to anti-HCV therapy.[7] The mean age of participants in this research was 48 years, meaning that many patients included in the new screening recommendation might receive these substantial benefits of anti-HCV treatment.

Furthermore, treatment of chronic HCV infection reduces the risk for hepatocellular carcinoma. In a meta-analysis of 18 studies, SVR reduced the relative risk for hepatocellular carcinoma to 0.24 compared with no SVR.[8] SVR was similarly effective in reducing the risk for hepatocellular carcinoma in an analysis confined to patients with advanced liver disease.

The new screening methods also appear to be cost-effective. In an analysis of the proposed birth-cohort HCV screening plan proposed by the USPSTF, researchers found that screening would result in over 800,000 new cases of HCV infection identified, at the cost of $2874 per case.[9] Subsequent treatment for HCV would result in costs of $15,000-$35,000 per quality-adjusted life-year gained, a favorable sum compared with other health interventions. In fact, another analysis found that age-based screening for HCV was more cost-effective than risk factor-based screening, although the authors stress that this is true only if all new cases receive standard triple therapy for their infection.[10]

Adding to the PCP Tasks
Primary care physicians are asked to do many things. The average number of patient requests of physicians per clinic visit was 5.5 in one study, and this information is now 14 years old.[11] These requests exclude other important elements of the office visit, such as addressing severe anemia or demonstrating empathy and patience when the patient bursts into tears upon being asked, "So, how's it going?"

Primary care physicians are also the stewards of preventive healthcare, which is a wonderful opportunity and distinct challenge. We need to get screening tests ordered on time for the right patients, and practice shared decision-making each step of the way as we do so.

At first glance, the new screening recommendations from the USPSTF may seem superfluous. However, after reviewing the epidemiology, treatment outcomes, and even cost-effectiveness data, this screening certainly appears to be prudent and beneficial. It should be embraced by primary care physicians. It should also evolve. As the demographics of HCV infection shift, the age-based screening approach will almost certainly need to change as well. An eventual move away from HCV screening will indicate a great victory for the public's health.

Clinical Pearls

• Between 1% and 2% of the adult population in the United States has been found to have chronic HCV infection, although this may be an underestimation once high-risk groups are added to the equation.
• Persons born between 1945 and 1965 bear a disproportionate share of the disease burden of chronic HCV infection, both in terms of higher prevalence and increased rates of complications.
• Treatment that results in SVR among patients with chronic HCV infection substantially reduces the risks for cirrhosis, hepatocellular carcinoma, and mortality.
• The new recommendations from the USPSTF support traditional screening for HCV among high-risk groups but also call for 1-time screening using anti-HCV antibody testing among adults born between 1945 and 1965. If used widely, this screening program should have a positive effect on morbidity and mortality among older adults.

  • Introduction
  • Background to the Study
  • Why Screen All Baby Boomers?
  • Limitations and Benefits
  • Clinical Pearls

    • Posted by at No comments:
    File Under ,

    NIH observes 20th anniversary of Women’s Interagency HIV Study


    NIH observes 20th anniversary of Women’s Interagency HIV Study

    The largest and longest-running study to investigate the impact of HIV on women in the United States marks its 20th anniversary this month. Findings from the Women’s Interagency HIV Study (WIHS) have helped define how best to treat HIV-infected women in the United States and globally.

    The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, established the WIHS in 1993 in response to a dramatic increase in AIDS cases among women in the United States. Since then, the WIHS has enrolled a total of 4,137 women who were HIV-infected or at risk for acquiring HIV, and has published more than 550 scientific papers . In so doing, the study has charted the course of HIV disease in treated and untreated women across the United States through detailed clinical, biological, neurocognitive, and behavioral assessments; comparisons of HIV-infected and uninfected women; and studies of HIV-infected women receiving treatment.

    The scientific accomplishments of the WIHS include assessing how genetic, metabolic, behavioral and other factors influence HIV disease progression. The study also has generated information on the health effects of other viruses in HIV-infected women, including herpes, hepatitis C and human papilloma viruses. These data have helped clarify how such co-infections impact the course not only of HIV disease, but also of cardiovascular, liver, and kidney disease; cervical cancer; diabetes; lipodystrophy (the redistribution of fat) and neurocognitive disorders. And the study has demonstrated that economically and socially disadvantaged women will volunteer to participate in intensive, long-term clinical studies and make important contributions to medical research.

    Today, nearly 2,120 women participate in the WIHS. More than 1,100 volunteers died from AIDS or other causes and 917 dropped out of the study. About 70 percent of the current participants are infected with HIV, and nearly 90 percent of those infected have taken antiretroviral therapy. The women are largely from minority groups, with 58 percent black, 28 percent Hispanic and 14 percent white. Roughly half of the participants live in poverty. These demographics of the WIHS volunteers reflect those of the HIV epidemic among women in the United States.

    Every six months since 1993, WIHS volunteers have made study visits to sites in Chicago, Los Angeles, New York City, San Francisco and Washington, D.C. New study sites were established this year in Atlanta; Birmingham, Ala.; Jackson, Miss.; Chapel Hill, N.C.; and Miami, while the Los Angeles site was closed. WIHS staff interview women about their health and behavior and conduct clinical and laboratory tests, and the data and specimens gathered during these visits are confidentially stored and managed in a central database in Baltimore and a repository in Frederick, Md.

    Since 1993 NIAID has continuously funded the WIHS in partnership with the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute on Drug Abuse, all part of NIH. The National Institute of Mental Health recently became a funding partner.

    NIH thanks the WIHS staff, scientists, and most importantly the volunteers, whose commitment and dedication over the past two decades have made the accomplishments of the WIHS possible.

    NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

    About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

    NIH...Turning Discovery Into Health®
    Posted by at No comments:
    File Under ,

    Hepatitis C: Gilead's experimental drug could flip current treatment paradigm on its head

    Gilead's sofosbuvir clears another HCV hurdle

    Full Text Available at NATAP
    Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial
    Or Download the PDF here 
    Related: Gilead's Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 shows promise in NIH trial

    Evidence continues to mount suggesting Gilead's experimental drug for hepatitis C virus could flip the current HCV treatment paradigm on its head.

    Results of the Phase II trial, sponsored and led by the National Institutes of Health, suggest that a regimen of sofosbuvir and ribavirin was highly effective in clearing the virus and well tolerated in two difficult-to-treat groups—patients with severe liver damage and African Americans. Both groups were comprised of those with genotype-1 HCV, which accounts for 70% of all HCV infections.

    The findings among patients with genotype 1, which appear in the current issue of JAMA, come on top of data showing strong efficacy for sofosbuvir in cohorts with genotypes 2 and 3. As such, analysts say the drug is poised to take the lion's share of the HCV market. A recent forecast from FactSet Research Systems put annual sales of sofosbuvir at $6.4 billion by 2017.

    In the current study, of the 60 enrolled volunteers, 50 were African American (88% of whom suffer from genotype 1 and are known to be harder to treat with interferon-based therapies).

    The bifurcated study broke out one group of 10 people with liver fibrosis. Fibrosis is part of the scarring process and represents the liver's response to injury.They received sofosbuvir and ribavirin. After 12 weeks of therapy, HCV was no longer present in all volunteers who completed therapy (nine out of 10).

    The other group consisted of 50 volunteers, including 13 with serious liver damage. They received sofousbuvir and either a dose of ribavirin based on weight or a low-dose ribavirin. From that group, 17 patients had no detectable levels of the virus 24 weeks after treatment stopped. Of the 22 volunteers who received the low-dose ribavirin, 12 were considered cured after the end of treatment. 

    In an NIH press release, researcher Dr. Shyam Kottilil summed up the findings, saying, “We saw an overall cure rate of about 70% using regimens that did not include interferon. This is an encouraging result, especially considering the proportion of volunteers who had characteristics…that are recognized as predictors of poor response to treatment.”

    The findings could make it harder for other prospective all-oral treatment regimens. Boehringer Ingelheim unveiled Phase II data earlier this month of its HCV combo of faldaprevir and deleobuvir, reporting high efficacy rates—85% in genotype 1b—but the sample did not include African Americans.

    Gilead's new drug application for sofosbuvir was filed in April. This initial application, under priority review, is for use in genotypes 2 and 3, and in the treatment-naïve for types 1, 4, 5 and 6.

    FDA expects to review the application by December 8, the agency said. The European Medicines Association, too, has given sofosbuvir an “accelerated assessment,” and if approved the drug could become available by the first half of next year.

    ISI Group analyst Mark Schoenebaum, in an investor note issued around the time of the FDA filing, wrote that “Gilead should be ready to launch an oral genotype 1 regime around the end of 2014.”

    http://www.mmm-online.com/gileads-sofosbuvir-clears-another-hcv-hurdle/article/309268/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+MMMHome+%28MMM+Home%29
    Posted by at No comments:
    File Under ,

    Broccoli and Joint Health

    Broccoli and Joint Health
    by Dr. Joe Galati
    08/28/2013


    Posted by at No comments:
    File Under ,

    Thursday, August 29, 2013

    Strong association of type 2 diabetes mellitus with HCV infection

    Journal of Diabetes Research
    Volume 2013 (2013), Article ID 539361, 7 pages
    http://dx.doi.org/10.1155/2013/539361

    Research Article

    Prevalence of Type 2 Diabetes Mellitus in Hepatitis C Virus Infected Population: A Southeast Asian Study
         Muhammad Sadik Memon, Zain Islam Arain, Farukh Naz, Madiha Zaki, Suresh Kumar, and Asif Ali Burney

    Isra University Hospital, Hala Naka Road, Hyderabad, Pakistan
    Received 16 April 2013; Revised 9 July 2013; Accepted 15 July 2013
    Academic Editor: Åke Lernmark

    Copyright © 2013 Muhammad Sadik Memon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Advancing age, increased weight, and HCV genotype 3 are independent predictors of type 2 diabetes in HCV seropositive patients, and there is a statistically significant association of cirrhosis observed with type 2 diabetes mellitus.

    Abstract

    Purpose
    The study was aimed to investigate the frequency of diabetes mellitus type 2 in patients infected with chronic hepatitis C virus and its association with cirrhosis.

    Patients and Methods
    This prospective case series was conducted at Section of Gastroenterology and Hepatology, Isra University Hospital, Hyderabad, over a period of 4 months from June 2009 to October 2009. Hepatitis C virus seropositive patients who were older than 18 years, diabetic or nondiabetic, were included. Basic demographic data collected by questionnaire and laboratory investigations including fasting blood glucose levels, serum cholesterol, and liver function tests were done. A logistic regression model was used to explore the association between diabetic and nondiabetic HCV seropositives and type 2 diabetes mellitus with cirrhosis.

    Results
    A total of 361 patients with hepatitis C were analyzed; the prevalence of type 2 diabetes mellitus in HCV patients was 31.5%. Out of the total number of the participants, 58.4% (n = 211) were cirrhotics, while 41.6% (n = 150) were noncirrhotic HCV seropositives. In multivariate analysis, cirrhotic patients appeared significantly more likely (P = 0.01) to be diabetic as compared with noncirrhotic patients (OR = 2.005, 95% CI: 1.15, 3.43).

    Conclusion
    Advancing age, increased weight, and HCV genotype 3 are independent predictors of type 2 diabetes in HCV seropositive patients, and there is a statistically significant association of cirrhosis observed with type 2 diabetes mellitus.

    1. Introduction
    Hepatitis C virus (HCV) has been identified as one of the leading causes of chronic liver disease with serious sequel as the end stage of cirrhosis and liver cancer [1]. According to recent statistics, the worldwide prevalence of HCV infection is ~3% and affects around more than 170 million people globally [2]. Chronic hepatitis C infection mainly affects liver but can be associated with various extrahepatic manifestations including cryoglobulinemia, sialadenitis, glomerulonephritis, and porphyria cutanea tarda [3, 4].

    Diabetes mellitus is a chronic disease of metabolism causing abnormal glucose homeostasis [5]. More than 171 million people globally are affected by diabetes mellitus, and the figure is expected to rise up to 366 million by 2030 [6]. A systemic review and meta-analysis from South Asia by Jayawardena et al. (2012) showed burden of diabetes in Pakistan ranging from 3% to 7.2% in a general population [7]. Type 2 diabetes mellitus in South Asian, when comparing with European individuals, is 4- to 6-fold more prevalent [8].

    Several studies reported that HCV infection may also contribute to the development of diabetes, and higher prevalence of type 2 diabetes mellitus has been observed in the developed world (2% to 9.4%) in patients with HCV infection than in those with other forms of chronic hepatitis [9–12]. This association between HCV infection and diabetes was for the first time made by Allison et al. in 1994 [13]. Since then, a number of observational studies have been published.

    There are several organized factors which influence the development of diabetes among HCV-infected patients like age, sex, family history of diabetes, African-American race, and HIV coinfection [14, 15].

    Insulin resistance (IR) and diabetes can develop at any stage of HCV infection. Multiple mechanisms have been accounted for insulin resistance and development of diabetes in patients with chronic hepatitis C. It promotes IR mainly through interfering with insulin signaling pathway in hepatocytes, increasing inflammatory response with production of cytokines such as TNF alpha and IL-6 and increasing oxidative stress [16, 17].

    There are many studies in the past done on frequency of diabetes in HCV infection. One such study was conducted by Elhawary et al. (2011) [15] that shows 13.84% prevalence of type 2 diabetes mellitus in HCV seropositive patients and also linked association of cirrhosis with diabetes mellitus.

    HCV infection and type 2 diabetes mellitus are two chronic conditions which contribute to a significant morbidity and mortality. The rationale behind this study is to find out the maximum number of type 2 diabetes in those patients who are infected with hepatitis C virus and also the relation between cirrhosis and type 2 diabetes mellitus seropositive patients; so in this way, we will establish a valid association between type 2 diabetes in HCV seropositive population.

    2. Patients and Methods
    This prospective study was conducted at Isra University Hospital (IUH), Section of Gastroenterology and Hepatology, Hyderabad. IUH is a 300-bedded private, tertiary care academic teaching hospital that largely serves the residents of Hyderabad (population 2 million) and the surrounding 6–8 districts of Sindh province. The study protocol was evaluated and approved by the hospital authorities, from where all the study participants were recruited, and the study was conducted in accordance with the Declaration of Helsinki Guidelines. All the individuals provided informed consent before their participation.

    3. Inclusion Criteria
    HCV seropositive patients, with or without presence of liver cirrhosis and/or diabetes mellitus type 2, between the age of 18 and 75 years, both males and females visiting the outpatient department or admitted in Gastroenterology and Hepatology Ward, were recruited consecutively during a period of 4 months from June 2009 to October 2009. Demographic information and all relevant data, such as area of residence and past medical history, were collected by trained nurses in a predesigned structured questionnaire.

    4. Exclusion Criteria
    Patients with liver cancer, on interferon therapy, having end stage renal disease or coexisting viral infection like hepatitis B surface antigen positive patients, and pregnant females were excluded from the research.

    5. Sample Collection
    Senior laboratory technologist drew 5 mL venous blood sample using a sterilized disposable syringe, and then the sample was used for the detection of hepatitis C virus by enzyme-linked immunosorbent assay (ELISA) and HCV genotyping determined by using polymerase chain reaction (PCR). Diagnosis of type 2 diabetes mellitus was done according to the American Diabetes Association guidelines (2013) [18]. Other laboratory investigations include complete blood picture, serum cholesterol, serum albumin, total bilirubin, prothrombin time, and serum creatinine levels. Liver cirrhosis was confirmed if the patient had previous recent reliable reports available or by using radiological investigations and liver biopsy where needed.

    6. Statistical Analysis
    For the comparison of participants of those with and without type 2 diabetes, Student’s -test was used for normality distributed continuous variables. Categorical variables were presented as frequency and percentage, and chi-square test was used for nominal categorical variables comparison. The prevalence of type 2 diabetes mellitus among seropositive patients was calculated and presented as percentage. Age was categorized in two groups (<40 years and ≥40 years); body mass index (BMI) was calculated by weight in kg/height meter squared and then categorized in two groups (<27 and ≥27). Multiple logistic regression model was introduced with the dependent variables such as age, gender, weight, BMI, family history of diabetes, and HCV genotype. Initially, in order to include important variables, factors having significance in univariate analysis were included in the multivariate analysis. The final model was selected using a forward method and . Data entry and analysis were done with Statistical Package for Social Sciences, version 16 (SPSS Inc, Chicago, IL, USA).

    7. Results
    The mean age of the study population (± standard deviation) was with a range of 18–75 years of age. Male and female proportions were almost equal in our study sample, 52.6% and 47.6%, respectively. The majority of the study populations were married (94.4%) as compared to the single ones (5.54%). Overall prevalence of type 2 diabetes mellitus among HCV seropositive patients was 31.5% (Table 1).

    Table 1: Demographic and clinical characteristics of study participants.
    CharacteristicHCV cases
     
    (%)    		Cirrhotic
     
    (%)    		Noncirrhotic
     
    (%)    		 value
    Age—years (mean SD) 0.001*
     Range18–7518–7518–75—
      18–40127 (35.1)44 (20.8)83 (55.3) 0.001*
      40234 (64.8)167 (79.1)67 (44.6)
    Gender    
     Male190 (52.6)124 (58.7)66 (44)0.006*
     Female171 (47.3)87 (41.2)84 (56)
    Residence    
     Urban171 (47.3)88 (41.7)83 (55.3)0.01*
     Rural190 (52.6)123 (58.2)67 (44.6)
    Education    
      5 years234 (64.8)124 (58.7)92 (61.3)0.24
      5 years127 (35.1)87 (41.2)58 (38.6)
    Marital status    
     Single20 (5.54)7 (3.31)13 (8.66)0.02*
     Married341 (94.4)204 (96.6)137 (91.3)
    Weight—kg    
    70232 (64.2)135 (63.9)97 (64.6)0.89
    70129 (35.7)76 (36.0)53 (35.3)
    BMI—kg/     
      27176 (48.7)108 (51.1)68 (45.3)0.27
      27185 (51.2)103 (48.8)82 (54.6)
    Type2 DM    
     Yes114 (31.5)81 (38.3)33 (22)0.001*
     No247 (68.5)130 (61.6)117 (78)
    Family history of DM    
     Yes109 (30.1)58 (27.4)51 (34)0.18
     No252 (69.8)153 (72.5)99 (66)
    Viral genotypes    
     Genotype 133 (9.14)31 (14.6)17 (11.3)0.73
     Genotype 23 (0.83)2 (0.94)1 (0.66)
     Genotype 3311 (86.1)171 (81.0)125 (83.3)
     Genotype 414 (3.87)7 (3.31)7 (4.66)
    Statistically significant value 0.05.
    DM: diabetes mellitus, BMI: body mass index.
    Statistically significant  value  0.05.DM: diabetes mellitus, BMI: body mass index.

    Statistically significant proportion of HCV seropositive patients with cirrhosis was ≥40 years old ( ). Other significant factors in HCV seropositive cirrhotics were male proportion, area of residence, marital status, and type 2 diabetes mellitus ( ) (Table 1).

    Table 2 shows comparison of means between type 2 diabetics and nondiabetic seropositive patients. In univariate analysis, mean age difference (4.71 years), fasting blood sugar (71.2 mg/dL), albumin (0.22 mg/dL), serum cholesterol (70.4 mg/dL), and serum creatinine (0.24 mg/dL) were statistically significant ( ) as compared with nondiabetic HCV seropositive patients (Table 2).

    Click On Table 2 To Enlarge



    On multivariate binominal analysis, age ≥40 years, weight ≥70 kg, family history of diabetes, and HCV genotype 3 were significantly more likely to be diabetic ( ). Likelihood of being type 2 diabetic in HCV seropositive cirrhotic patients was significant in univariate analysis ( ), and in multivariate analysis, this association was observed two times higher as compared with noncirrhotic patients (OR = 2.005, 95% CI: 1.15, 3.43) (Table 3).

    Click On Table 3 To Enlarge



    We observed the prevalence of type 2 diabetes as 31.5% (114 cases) out of 361 hepatitis C seropositive patients. When we compared the prevalence of type 2 diabetes in HCV-infected population and noninfected population, a twice higher rate of type 2 diabetes was observed in our study as compared to noninfected population [19]. White et al. (2008) [20] analyzed 34 eligible retrospective and prospective studies, showing a significant risk of type 2 diabetes in HCV-infected group as compared to non-HCV-infected control group. On the other hand, recent data also suggest three times higher prevalence of type 2 diabetes in HCV seropositive patients [21]. In this way, data from the previous literature and from our study show a strong association between HCV and type 2 diabetes. Several reasons can explain the association of type 2 diabetes with HCV. One of the explanations is that the pathophysiology of HCV-associated type 2 diabetes mellitus consists of a defect in insulin secretion, increased hepatic tumor necrosis factor alpha, excessive hepatic glucose production, and insulin resistance, because the core-encoding region of HCV is sufficient to induce insulin resistance by the previously defined mechanism via either direct or indirect way [22]. Secondly, a major contribution of already present risk factors of diabetes such as positive family history and advancing age also plays an important role among HCV infected persons [23, 24].

    Advancing age (≥40 years) in HCV seropositive patients was significantly associated with type 2 diabetes mellitus as compared to younger age group (≥18 to 40 years) on both univariate and multivariate analyses. The finding also agrees with another study conducted earlier on Mexican population [25].

    It was observed in our study that positive cases of type 2 diabetes with respect to gender, education level, and marital status had insignificant relation. A study conducted by Elhawary et al., 2011, also revealed the same findings as in our study [15]; this could be because of the same number of patients attending the hospital, but this insignificant association between seropositive patients cannot be neglected, as in the general population, type 2 diabetes was more prevalent in males than in females [26, 27]; this relationship should be evaluated further on larger scale studies.

    Fasting blood glucose levels and total serum cholesterol levels were significantly observed when diabetic compared with nondiabetic HCV seropositive patients. Substantial evidence from the previous literature shows significant association between these laboratory findings [15, 21]. Additionally, patients with HCV and type 2 diabetes may involve kidneys and patients may present with acute renal failure during its later stages [4] which can be observed through significant association of raised serum creatinine in diabetic HCV positive patients [28]. In our study, an increase in mean serum creatinine was significantly observed in HCV patients with type 2 diabetes as compared to HCV patients who were not diabetic.

    The most common genotype in our study was genotype 3 which constituted >85% of the whole sample. Previous literatures from Pakistan favor our findings [29–32]; as HCV genotype 3 is more common in Pakistan [33]. Controversies regarding the presence of a specific genotype in HCV seropositive diabetic patient are still a part of scientific debate, and larger scale studies are required to find a conclusion regarding which genotype is more specifically affecting diabetic HCV seropositive patients [34–36]. However, our study observed that the HCV seropositive population with genotype 3 was significantly associated with type 2 diabetes mellitus. This significant association could be due to genotype 3 in our study comprises of more than third portion of whole HCV diabetic population.

    Our study also observed that odds of being type 2 diabetics among HCV-infected patients with cirrhosis was doubled ( ) as compared to noncirrhotic HCV seropositive patients. Importantly, studies published in other areas also describe similar trends, in which type 2 diabetes mellitus is more frequently observed in patients with cirrhosis as compared to noncirrhotics, and it ranges from 19.5% to 50% [37–40]. This relationship proves that with advancing liver disease there will be increased susceptibility of HCV seropositive patients to develop type 2 diabetes mellitus.

    9. Study Limitations
    There are certain limitations of this study. The most important limitations in this study are small sample size, single-centered-hospital-based study, and only included HCV seropositives which may be unable to reflect the actual incidence of type 2 diabetes in HCV seropositives.

    10. Conclusion and Recommendation
    This study concludes that there is a strong association of type 2 diabetes mellitus with HCV infection. Odds of development of type 2 diabetes increases by twofolds if an HCV patient has cirrhosis. Advancing age, increased weight, and HCV genotype 3 are independent predictors of type 2 diabetes in HCV seropositive patients. It is necessary to screen and control earlier for the presence of type 2 diabetes mellitus and also rule out HCV infection among diabetic populations which is rarely done on population-based studies.

    Authors’ Contribution
    Muhammad Sadik Memon and Zain Islam Arain conceived the idea and the design of this study. Farukh Naz and Madiha Zaki were involved in the drafting of questionnaire and the collection of data. Muhammad Sadik Memon and Zain Islam Arain analyzed the data and wrote the initial draft of this paper. Asif Ali Burney, and Suresh Kumar were the principal supervisors during the data collection. All authors approved the final draft for publication.

    References
    A. A. Elfiky, W. M. Elshemey, W. A. Gawad, and O. S. Desoky, “Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes,” The Protein Journal, vol. 32, no. 1, pp. 75–80, 2013. View at Publisher · View at Google Scholar
    R. N. Gacche and S. K. Al-Mohani, “Seroprevalence and risk factors for hepatitis C virus infection among general population in central region of Yemen,” Hepatitis Research and Treatment, vol. 2012, Article ID 689726, 4 pages, 2012. View at Publisher · View at Google Scholar
    F. Fabrizi, E. Plaisier, D. Saadoun, P. Martin, P. Messa, and P. Cacoub, “Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease,” American Journal of Kidney Diseases, vol. 61, no. 4, pp. 623–637, 2013.
    H. M. Ko, J. C. Hernandez-Prera, H. Zhu, et al., “Morphologic features of extrahepatic manifestations of hepatitis C virus infection,” Clinical and Developmental Immunology, vol. 2012, Article ID 740138, 9 pages, 2012. View at Publisher · View at Google Scholar
    K. Imam, “Clinical features, diagnostic criteria and pathogenesis of diabetes mellitus,” Advances in Experimental Medicine and Biology, vol. 771, pp. 340–355, 2012.
    N. Gul, “Knowledge, attitudes and practices of type 2 diabetic patients,” Journal of Ayub Medical College, Abbottabad, vol. 22, no. 3, pp. 128–131, 2010. View at Scopus
    R. Jayawardena, P. Ranasinghe, N. M. Byrne, M. J. Soares, P. Katulanda, and A. P. Hills, “Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis,” BMC Public Health, vol. 12, p. 380, 2012.
    S. D. Rees, M. Z. I. Hydrie, J. P. O'Hare et al., “Effects of 16 genetic variants on fasting glucose and type 2 diabetes in South Asians: ADCY5 and GLIS3 variants may predispose to type 2 diabetes,” PLoS ONE, vol. 6, no. 9, Article ID e24710, 2011. View at Publisher · View at Google Scholar · View at Scopus
    A. Lonardo, L. E. Adinolfi, S. Petta, A. Craxi, and P. Loria, “Hepatitis C and diabetes: the inevitable coincidence?” Expert Review of Anti-Infective Therapy, vol. 7, no. 3, pp. 293–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
    F. Negro and M. Alaei, “Hepatitis C virus and type 2 diabetes,” World Journal of Gastroenterology, vol. 15, no. 13, pp. 1537–1547, 2009. View at Publisher · View at Google Scholar · View at Scopus
    Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, and E. Elsheikh, “Associations of chronic hepatitis C with metabolic and cardiac outcomes,” Alimentary Pharmacology & Therapeutics, vol. 37, no. 6, pp. 647–652, 2013.
    C. Naing, J. W. Mak, S. I. Ahmed, and M. Maung, “Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis,” World Journal of Gastroenterology, vol. 18, no. 14, pp. 1642–1651, 2012. View at Publisher · View at Google Scholar · View at Scopus
    M. E. D. Allison, T. Wreghitt, C. R. Palmer, and G. J. M. Alexander, “Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population,” Journal of Hepatology, vol. 21, no. 6, pp. 1135–1139, 1994. View at Publisher · View at Google Scholar · View at Scopus
    A. Lecube, C. Hernández, J. Genescà, and R. Simó, “Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis,” Diabetes Care, vol. 29, no. 5, pp. 1140–1149, 2006. View at Publisher · View at Google Scholar · View at Scopus
    E. I. Elhawary, G. F. Mahmoud, M. A. El-Daly, F. A. Mekky, G. G. Esmat, and M. Abdel-Hamid, “Association of HCV with diabetes mellitus: an Egyptian case-control study,” Virology Journal, vol. 8, article 367, 2011. View at Publisher · View at Google Scholar · View at Scopus
    B. L. Pearlman and N. Traub, “Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more,” Clinical Infectious Diseases, vol. 52, no. 7, pp. 889–900, 2011. View at Publisher · View at Google Scholar · View at Scopus
    C.-H. Hung, C.-M. Lee, and S.-N. Lu, “Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications,” Expert Review of Anti-Infective Therapy, vol. 9, no. 5, pp. 525–533, 2011. View at Publisher · View at Google Scholar · View at Scopus
    ADA American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 36, no. S1, pp. S11–S66, 2013.
    M. F. Tareen, K. Shafique, S. S. Mirza, Z. I. Arain, I. Ahmad, and P. Vart, “Location of residence or social class, which is the stronger determinant associated with cardiovascular risk factors among Pakistani population? A cross sectional study,” Rural and Remote Health, vol. 11, no. 3, p. 1700, 2011. View at Scopus
    D. L. White, V. Ratziu, and H. B. El-Serag, “Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis,” Journal of Hepatology, vol. 49, no. 5, pp. 831–844, 2008. View at Publisher · View at Google Scholar · View at Scopus
    S. Ali, S. Abera, A. Mihret, and T. Abebe, “Association of hepatitis C virus infection with type II diabetes in Ethiopia: a hospital-based case-control study,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2012, Article ID 354656, 7 pages, 2012. View at Publisher · View at Google Scholar
    P.-S. Hsieh and Y.-J. Hsieh, “Impact of liver diseases on the development of type 2 diabetes mellitus,” World Journal of Gastroenterology, vol. 17, no. 48, pp. 5240–5245, 2011. View at Publisher · View at Google Scholar · View at Scopus
    S. Costantini, F. Capone, E. Guerriero, et al., “Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection,” PLoS ONE, vol. 7, no. 6, Article ID e39486, 2012. View at Publisher · View at Google Scholar
    M. Stepanova, B. Lam, Y. Younossi, M. K. Srishord, and Z. M. Younossi, “Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity,” Journal of Viral Hepatitis, vol. 19, no. 5, pp. 341–345, 2012. View at Publisher · View at Google Scholar · View at Scopus
    E. Chiquete, A. Ochoa-Guzmán, L. García-Lamas, et al., “Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients,” Revista Médica del Instituto Mexicano del Seguro Social, vol. 50, no. 5, pp. 481–486, 2012.
    A. S. Shera, A. Basit, A. Fawwad et al., “Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in the Punjab Province of Pakistan,” Primary Care Diabetes, vol. 4, no. 2, pp. 79–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
    T. Wilke, P. Ahrendt, D. Schwartz, R. Linder, S. Ahrens, and F. Verheyen, “Incidence and prevalence of type 2 diabetes mellitus in Germany: an analysis based on 5.43 million patients,” The Deutsche Medizinische Wochenschrift, vol. 138, no. 3, pp. 69–75, 2013.
    A. Ali and N. N. Zein, “Hepatitis C infection: a systemic disease with extrahepatic manifestations,” Cleveland Clinic Journal of Medicine, vol. 72, no. 11, pp. 1005–1019, 2005. View at Publisher · View at Google Scholar · View at Scopus
    H. Aziz, A. Raza, S. Murtaza, et al., “Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis,” International Journal of Infectious Diseases, vol. 17, no. 4, pp. e247–e253, 2013. View at Publisher · View at Google Scholar
    S. Qureshi, M. Shafiei-Guilani, and S. H. Aalaei-Andabili, “Why is the sustained virological response rate among HCV genotype 3 infected patients in Pakistan low?” Journal of College of Physicians and Surgeons Pakistan, vol. 22, no. 1, pp. 70–71, 2012.
    A. Ali, M. Nisar, H. Ahmad, N. Saif, M. Idrees, and M. A. Bajwa, “Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan,” Virology Journal, vol. 8, article 466, 2011. View at Publisher · View at Google Scholar · View at Scopus
    K. Mahmood, N. Mohammad, and Abidullah, “Genotype variation of hepatitis C virus in District Buner Swat,” Journal of Ayub Medical College, Abbottabad, vol. 23, no. 4, pp. 18–21, 2011.
    S. Attaullah, S. Khan, and I. Ali, “Hepatitis C virus genotypes in Pakistan: a systemic review,” Virology Journal, vol. 8, article 433, 2011. View at Publisher · View at Google Scholar · View at Scopus
    A. Lecube, C. Hernández, J. Genescà, J. I. Esteban, R. Jardí, and R. Simó, “High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury,” Diabetes Care, vol. 27, no. 5, pp. 1171–1175, 2004. View at Publisher · View at Google Scholar · View at Scopus
    J. M. Hui, A. Sud, G. C. Farrell et al., “Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression,” Gastroenterology, vol. 125, no. 6, pp. 1695–1704, 2003. View at Publisher · View at Google Scholar · View at Scopus
    I. H. Y. Cua, J. M. Hui, J. G. Kench, and J. George, “Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C,” Hepatology, vol. 48, no. 3, pp. 723–731, 2008. View at Publisher · View at Google Scholar · View at Scopus
    A. L. Mason, J. Y. N. Lau, N. Hoang et al., “Association of diabetes mellitus and chronic hepatitis C virus infection,” Hepatology, vol. 29, no. 2, pp. 328–333, 1999. View at Publisher · View at Google Scholar · View at Scopus
    N. Wlazlo, H. J. B. H. Beijers, E. J. Schoon, H. P. Sauerwein, C. D. A. Stehouwer, and B. Bravenboer, “High prevalence of diabetes mellitus in patients with liver cirrhosis,” Diabetic Medicine, vol. 27, no. 11, pp. 1308–1311, 2010. View at Publisher · View at Google Scholar · View at Scopus
    A. Singal and A. Ayoola, “Prevalence and factors affecting occurrence of type 2 diabetes mellitus in Saudi patients with chronic liver disease,” Saudi Journal of Gastroenterology, vol. 14, no. 3, pp. 118–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
    M. B. Parolin, F. E. Zaina, M. V. Araújo, É. Kupka, and J. C. U. Coelho, “Prevalence of type 2 diabetes mellitus in Brazilian liver transplant candidates: negative association with HCV status,” Transplantation Proceedings, vol. 36, no. 9, pp. 2774–2775, 2004. View at Publisher · View at Google Scholar · View at Scopus
    Posted by at No comments:
    File Under , , ,
    Subscribe to: Posts (Atom)